Moreover, patients with a loss of HER2 from primary BC to recurrent disease survived 21.0 months longer in comparison to patients with a gain of HER2, but the Kaplan–Meier analysis showed that the difference was not significant (p = 0.177). This evidence concerns the gene ERBB2 and breast cancer.